Venous and Arterial Thromboembolic Complications Associated with HIV Infection and Highly Active Antiretroviral Therapy

Abstract

With the advent of highly active antiretroviral therapy (HAART), dramatic improvements have been made in the quality and length of life in people living with HIV/AIDS (PLWA). Complications that are seen with increasing frequency in this group include venous thromboembolism events (VTE) and cardiovascular disease. Recent epidemiologic studies suggest PLWA have a 2-fold to 10-fold greater risk of VTE compared with age-matched controls. Several mechanisms associated with HIV infection, coupled with traditional risk factors, including age, opportunistic infections, and lifestyle choices, may contribute to a heightened risk of VTE and cardiovascular disease. It has been challenging to discern which of these complications are related to HAART. Herein, we review the risk of VTE in the pre-HAART and current HAART era. We call attention to particular instances where components of HAART have been associated with acute myocardial infarction, noncirrhotic portal hypertension and portal vein thrombosis. We also highlight potential drug–drug interactions between HAART and anticoagulant therapy. Additional studies are needed to better understand the mechanisms and risks associated with long-term use of HAART and to what extent HAART contributes to or mitigates the risk of VTE and cardiovascular disease.

Keywords

drug interactions - HAART - HIV/AIDS - myocardial infarction - thrombosis

• References

• 1 Thompson MA, Aberg JA, Cahn P , et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304 (3) 321-333
• 2 Panel on Antiretroviral Guidelines for Adults and Adolescents, Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Available at: http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf . Accessed September 17, 2012
• 3 Sterne JA, Hernán MA, Ledergerber B , et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005; 366 (9483) 378-384
• 4 Walensky RP, Paltiel AD, Losina E , et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194 (1) 11-19
• 5 Aboulafia D. An update on HIV-associated venous thromboembolism in the era of highly active antiretroviral therapy. J Coagul Disord 2010; 2: 49-56
• 6 Crum-Cianflone NF, Weekes J, Bavaro M. Review: thromboses among HIV-infected patients during the highly active antiretroviral therapy era. AIDS Patient Care STDS 2008; 22 (10) 771-778
• 7 Eyal A, Veller M. HIV and venous thrombotic events. S Afr J Surg 2009; 47 (2) 54-56
• 8 Cruciani M, Zanichelli V, Spelloni G , et al. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS 2011; 25: 1993-2004
• 9 Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348 (8) 702-710
• 10 Vispo E, Moreno A, Maida I , et al. Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings. AIDS 2010; 24 (8) 1171-1176
• 11 Mallet VO, Varthaman A, Lasne D , et al. Acquired protein S deficiency leads to obliterative portal venopathy and to compensatory nodular regenerative hyperplasia in HIV-infected patients. AIDS 2009; 23 (12) 1511-1518
• 12 Kovari H, Weber R. Influence of antiretroviral therapy on liver disease. Curr Opin HIV AIDS 2011; 6 (4) 272-277
• 13 World Health Organization. Global HIV/AIDS response: epidemic update and health sector progress towards universal access: progress report 2011. Geneva, Switzerland: World Health Organization; 2011
• 14 Klein SK, Slim EJ, de Kruif MD , et al. Is chronic HIV infection associated with venous thrombotic disease? A systematic review. Neth J Med 2005; 63 (4) 129-136
• 15 Sullivan PS, Dworkin MS, Jones JL, Hooper WC. Epidemiology of thrombosis in HIV-infected individuals. The adult/adolescent spectrum of HIV disease project. AIDS 2000; 14 (3) 321-324
• 16 Fultz SL, McGinnis KA, Skanderson M, Ragni MV, Justice AC. Association of venous thromboembolism with human immunodeficiency virus and mortality in veterans. Am J Med 2004; 116 (6) 420-423
• 17 Saber AA, Aboolian A, LaRaja RD, Baron H, Hanna K. HIV/AIDS and the risk of deep vein thrombosis: a study of 45 patients with lower extremity involvement. Am Surg 2001; 67 (7) 645-647
• 18 Malek J, Rogers R, Kufera J, Hirshon JM. Venous thromboembolic disease in the HIV-infected patient. Am J Emerg Med 2011; 29 (3) 278-282
• 19 Copur AS, Smith PR, Gomez V, Bergman M, Homel P. HIV infection is a risk factor for venous thromboembolism. AIDS Patient Care STDS 2002; 16 (5) 205-209
• 20 Saif MW, Bona R, Greenberg B. AIDS and thrombosis: retrospective study of 131 HIV-infected patients. AIDS Patient Care STDS 2001; 15 (6) 311-320
• 21 Jenkins RE, Peters BS, Pinching AJ. Thromboembolic disease in AIDS is associated with cytomegalovirus disease. AIDS 1991; 5 (12) 1540-1542
• 22 Hassell KL, Kressin DC, Neumann A, Ellison R, Marlar RA. Correlation of antiphospholipid antibodies and protein S deficiency with thrombosis in HIV-infected men. Blood Coagul Fibrinolysis 1994; 5 (4) 455-462
• 23 Laing RB, Brettle RP, Leen CL. Venous thrombosis in HIV infection. Int J STD AIDS 1996; 7 (2) 82-85
• 24 George SL, Swindells S, Knudson R, Stapleton JT. Unexplained thrombosis in HIV-infected patients receiving protease inhibitors: report of seven cases. Am J Med 1999; 107 (6) 624-630
• 25 Howling SJ, Shaw PJ, Miller RF. Acute pulmonary embolism in patients with HIV disease. Sex Transm Infect 1999; 75 (1) 25-29
• 26 Matta F, Yaekoub AY, Stein PD. Human immunodeficiency virus infection and risk of venous thromboembolism. Am J Med Sci 2008; 336 (5) 402-406
• 27 Rasmussen LD, Dybdal M, Gerstoft J , et al. HIV and risk of venous thromboembolism: a Danish nationwide population-based cohort study. HIV Med 2011; 12 (4) 202-210
• 28 Ahonkhai AA, Gebo KA, Streiff MB, Moore RD, Segal JB. Venous thromboembolism in patients with HIV/AIDS: a case-control study. J Acquir Immune Defic Syndr 2008; 48 (3) 310-314
• 29 Louw S, Jacobson BF, Büller H. Human immunodeficiency virus infection and acute deep vein thromboses. Clin Appl Thromb Hemost 2008; 14 (3) 352-355
• 30 Jansen JM, Lijfering WM, Sprenger HG, van der Meer J, van Pampus MG. Venous thromboembolism in HIV-positive women during puerperium: a case series. Blood Coagul Fibrinolysis 2008; 19 (1) 95-97
• 31 Nagaraja V, Terriquez JA, Gavini H, Jha L, Klotz SA. Pulmonary embolism mimicking pneumonia in a HIV patient. Case Report Med 2010; June14: [Epub ahead of print]
• 32 Jacobson MC, Dezube BJ, Aboulafia DM. Thrombotic complications in patients infected with HIV in the era of highly active antiretroviral therapy: a case series. Clin Infect Dis 2004; 39 (8) 1214-1222
• 33 Jong E, Louw S, Meijers JC , et al. The hemostatic balance in HIV-infected patients with and without antiretroviral therapy: partial restoration with antiretroviral therapy. AIDS Patient Care STDS 2009; 23 (12) 1001-1007
• 34 Kiser KL, Badowski ME. Risk factors for venous thromboembolism in patients with human immunodeficiency virus infection. Pharmacotherapy 2010; 30 (12) 1292-1302
• 35 Baker JV, Lundgren JD. Cardiovascular implications from untreated human immunodeficiency virus infection. Eur Heart J 2011; 32 (8) 945-951
• 36 Funderburg NT, Mayne E, Sieg SF , et al. Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood 2010; 115 (2) 161-167
• 37 Musselwhite LW, Sheikh V, Norton TD , et al. Markers of endothelial dysfunction, coagulation and tissue fibrosis independently predict venous thromboembolism in HIV. AIDS 2011; 25 (6) 787-795
• 38 Koppel K, Bratt G, Schulman S, Bylund H, Sandström E. Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 29 (5) 441-449
• 39 Carr A, Samaras K, Burton S , et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12 (7) F51-F58
• 40 Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 2003; 17 (Suppl. 01) S141-S148
• 41 Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352 (1) 48-62
• 42 Barbaro G. Heart and HAART: two sides of the coin for HIV-associated cardiology issues. World J Cardiol 2010; 2 (3) 53-57
• 43 Calmy A, Gayet-Ageron A, Montecucco F , et al. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS 2009; 23 (8) 929-939
• 44 Rosendaal FR. Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis. Thromb Haemost 1997; 78 (1) 1-6
• 45 Torriani FJ, Komarow L, Parker RA , et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: the ACTG (AIDS Clinical Trials Group) study 5152s. J Am Coll Cardiol 2008; 52 (7) 569-576
• 46 Chai H, Yang H, Yan S , et al. Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries. J Acquir Immune Defic Syndr 2005; 40 (1) 12-19
• 47 Friis-Møller N, Reiss P, Sabin CA , et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356 (17) 1723-1735
• 48 Dubé MP, Lipshultz SE, Fichtenbaum CJ , et al. Effects of HIV infection and antiretroviral therapy on the heart and vasculature. Circulation 2008; 118 (2) e36-e40
• 49 Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay CL. Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Québec's public health insurance database. J Acquir Immune Defic Syndr 2011; 57 (3) 245-253
• 50 Obel N, Farkas DK, Kronborg G , et al. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Med 2010; 11 (2) 130-136
• 51 Sabin CA, Worm SW, Weber R , et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371 (9622) 1417-1426
• 52 Podzamczer D, Ferrer E, Sanchez P , et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 2007; 44 (2) 139-147
• 53 Fätkenheuer G, Duvivier C, Rieger A , et al. Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial. J Antimicrob Chemother 2012; 67 (3) 685-690
• 54 Strategies for Management of Anti-Retroviral Therapy/INSIGHT, DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22 (14) F17-F24
• 55 Lang S, Mary-Krause M, Cotte L , et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010; 170 (14) 1228-1238
• 56 Bedimo RJ, Westfall AO, Drechsler H, Vidiella G, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis 2011; 53 (1) 84-91
• 57 Brothers CH, Hernandez JE, Cutrell AG , et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr 2009; 51 (1) 20-28
• 58 Padilla S, Masiá M, García N, Jarrin I, Tormo C, Gutiérrez F. Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir. BMC Infect Dis 2011; 11: 40
• 59 Ding X, Andraca-Carrera E, Cooper C , et al. No association of myocardial infarction with ABC use: an FDA meta-analysis. 18th Conference on Retroviruses and Opportunistic Infections 2011;paper #808.
• 60 European AIDS Clinical Society. EACS HIV guidelines. PARIS, France: European AIDS Clinical Society; 2011. Available at: http://www.europeanaidsclinicalsociety.org . Accessed September 17, 2012
• 61 Behrens GM. Abacavir and myocardial infarctions: the benefit of doubt?. AIDS 2011; 25 (16) 2043-2045
• 62 Maida I, Garcia-Gasco P, Sotgiu G , et al. Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome. Antivir Ther 2008; 13 (1) 103-107
• 63 Bihl F, Janssens F, Boehlen F, Rubbia-Brandt L, Hadengue A, Spahr L. Anticoagulant therapy for nodular regenerative hyperplasia in a HIV-infected patient. BMC Gastroenterol 2010; 10: 6
• 64 Scourfield A, Waters L, Holmes P , et al. Non-cirrhotic portal hypertension in HIV-infected individuals. Int J STD AIDS 2011; 22 (6) 324-328
• 65 Mendizabal M, Craviotto S, Chen T, Silva MO, Reddy KR. Noncirrhotic portal hypertension: another cause of liver disease in HIV patients. Ann Hepatol 2009; 8 (4) 390-395
• 66 Soriano V, Puoti M, Garcia-Gascó P , et al. Antiretroviral drugs and liver injury. AIDS 2008; 22 (1) 1-13
• 67 Fihn SD, McDonell M, Martin D , et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Ann Intern Med 1993; 118 (7) 511-520
• 68 Goldstein K, Gluckman S, Mounzer K. Challenge of co-administering antiretroviral therapy and oral anticoagulants in HIV-positive patients. AIDS Read 2008; 18 (9) 480-482 , 486–489
• 69 Welzen ME, van den Berk GE, Hamers RL, Burger DM. Interaction between antiretroviral drugs and acenocoumarol. Antivir Ther 2011; 16 (2) 249-252
• 70 Holbrook AM, Pereira JA, Labiris R , et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165 (10) 1095-1106
• 71 Liedtke MD, Rathbun RC. Warfarin-antiretroviral interactions. Ann Pharmacother 2009; 43 (2) 322-328
• 72 Thompson III GR, Lawrence VA, Crawford GE. HIV infection increases the risk of heparin-induced thrombocytopenia. Clin Infect Dis 2007; 45 (10) 1393-1396
• 73 Racoosin JA, Kessler CM. Bleeding episodes in HIV-positive patients taking HIV protease inhibitors: a case series. Haemophilia 1999; 5 (4) 266-269
• 74 Pollmann H, Richter H, Jürgens H. Platelet dysfunction as the cause of spontaneous bleeding in two haemophilic patients taking HIV protease inhibitors. Thromb Haemost 1998; 79 (6) 1213-1214
• 75 Graff J, von Hentig N, Kuczka K , et al. Significant effects of tipranavir on platelet aggregation and thromboxane B2 formation in vitro and in vivo. J Antimicrob Chemother 2008; 61 (2) 394-399
• 76 Becattini C, Agnelli G, Schenone A , et al; WARFASA Investigators. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366 (21) 1959-1967
• 77 Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012; 172 (5) 397-402
• 78 Hsue PY, Scherzer R, Grunfeld C , et al. HIV infection is associated with decreased thrombin generation. Clin Infect Dis 2012; 54 (8) 1196-1203